18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy.
Gaurav MalviyaRachana PatelMark SaljiRafael S MartinezPeter RepiscakErnest MuiSusan ChampionAgata MrowinskaEmma JohnsonMaha AlRasheediSally PimlottDavid LewisHing Y LeungPublished in: EJNMMI research (2020)
We studied in vivo 18F-Fluciclovine uptake in human prostate cancer orthograft models following acute and chronic ADT. 18F-Fluciclovine uptakes highlight tumour heterogeneity that may explain castration resistance and can be exploited as a clinical biomarker.
Keyphrases
- pet ct
- prostate cancer
- radical prostatectomy
- single cell
- endothelial cells
- liver failure
- positron emission tomography
- high resolution
- drug induced
- respiratory failure
- stem cells
- aortic dissection
- pluripotent stem cells
- mesenchymal stem cells
- intensive care unit
- acute respiratory distress syndrome
- fluorescence imaging